Ana Slipicevic
Overview
Explore the profile of Ana Slipicevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marttila P, Bonagas N, Chalkiadaki C, Stigsdotter H, Schelzig K, Shen J, et al.
Mol Oncol
. 2024 Mar;
18(9):2179-2195.
PMID: 38533616
The one-carbon metabolism enzyme bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is among the most overexpressed proteins across tumors and is widely recognized as a promising anticancer target. While MTHFD2 is mainly...
2.
Green A, Marttila P, Kiweler N, Chalkiadaki C, Wiita E, Cookson V, et al.
Nat Metab
. 2023 Apr;
5(4):642-659.
PMID: 37012496
Cancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase-cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor...
3.
Gebraad A, Ohlsbom R, Miettinen J, Emeh P, Pakarinen T, Manninen M, et al.
Cells
. 2022 May;
11(9).
PMID: 35563880
Mesenchymal stem/stromal cells (MSCs) are self-renewing and multipotent progenitors, which constitute the main cellular compartment of the bone marrow stroma. Because MSCs have an important role in the pathogenesis of...
4.
Flanagan K, Kumari R, Miettinen J, Haney S, Varney M, Williams J, et al.
Hemasphere
. 2022 Mar;
6(3):e687.
PMID: 35243210
Immunoglobulin light-chain (AL) amyloidosis is a rare disease caused by clonal plasma cell secretion of misfolded light chains that assemble as toxic amyloid fibrils, depositing in vital organs including the...
5.
Byrgazov K, Lind T, Rasmusson A, Andersson C, Slipicevic A, Lehmann F, et al.
Bone Rep
. 2021 Jun;
15:101098.
PMID: 34150958
Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes...
6.
Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, et al.
Hemasphere
. 2021 Jun;
5(7):e602.
PMID: 34136753
Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to...
7.
Miettinen J, Kumari R, Traustadottir G, Huppunen M, Sergeev P, Majumder M, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33810334
Multiple myeloma (MM) is characterized by extensive immunoglobulin production leading to an excessive load on protein homeostasis in tumor cells. Aminopeptidases contribute to proteolysis by catalyzing the hydrolysis of amino...
8.
Juraleviciute M, Nsengimana J, Newton-Bishop J, Hendriks G, Slipicevic A
Cancer Med
. 2021 Mar;
10(8):2840-2854.
PMID: 33734579
MX2 is an interferon inducible gene that is mostly known for its antiviral activity. We have previously demonstrated that MX2 is also associated with the tumorigenesis process in melanoma. However,...
9.
Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, et al.
Leuk Res
. 2021 Jan;
101:106499.
PMID: 33422770
No abstract available.
10.
Byrgazov K, Anderson C, Salzer B, Bozsaky E, Larsson R, Gullbo J, et al.
Ther Adv Med Oncol
. 2020 Aug;
12:1758835920937891.
PMID: 32774473
Background: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS...